FIA
KAPA

FNY Investment Advisers’s Kairos Pharma KAPA Stock Holding History

FNY Investment Advisers’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,500
Closed -$27K – 1594
2025
Q3 		$27K Buy
+23,500
New +$26.9K 0.01% 633

Other funds holding KAPA

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

FNY Investment Advisers's KAPA Position: Q4 2025 in Review

FNY Investment Advisers sold out of Kairos Pharma (KAPA) in Q4 2025, closing a stake of 23,500 shares — an estimated $27K sold.

FNY Investment Advisers first reported a position in KAPA in Q3 2025 and held it in 1 quarter. The position peaked at $27K in Q3 2025. 14 funds tracked by Wall St. Rank hold KAPA as of Q4 2025.

  • FNY Investment Advisers reported no remaining Kairos Pharma position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 23,500 Kairos Pharma shares in Q4 2025, an estimated $27K.
  • FNY Investment Advisers first reported a position in Kairos Pharma in Q3 2025 and held it in 1 quarter.
  • FNY Investment Advisers's Kairos Pharma position peaked at $27K in Q3 2025.
  • 14 funds tracked by Wall St. Rank held Kairos Pharma as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.